Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating GDC-8264 to prevent cardiac surgery-associated acute kidney injury and major adverse kidney events was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Drugs mentioned

• GDC-8264

Snippet

Sponsor: Genentech, Inc. | Conditions: Acute Kidney Injury | Phase 2 | Status: TERMINATED